Correction: Delphinidin-3-Glucoside Protects against Oxidized Low-Density Lipoprotein-Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via the Sodium-Dependent Glucose Transporter SGLT1

Correction: Delphinidin-3-Glucoside Protects against Oxidized Low-Density Lipoprotein-Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via the Sodium-Dependent Glucose Transporter SGLT1

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908741/?tool=EBI

Similar Items

Delphinidin-3-glucoside protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells via the sodium-dependent glucose transporter SGLT1.
by: Xin Jin, et al.
Published: (2013-01-01)

Correction: Delphinidin-3-Glucoside Protects against Oxidized Low-Density Lipoprotein-Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via the Sodium-Dependent Glucose Transporter SGLT1.
by: Xin Jin, et al.
Published: (2014-01-01)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Method validation of delphinidin-3-o-glucoside chloride in rat plasma by High-Performance Liquid Chromatography (HPLC)
by: Shafawi, Nur Atielah Nabila Mohd
Published: (2022)

Delphinidin-3-O-glucoside inhibits angiogenesis via VEGFR2 downregulation and migration through actin disruption
by: Olga Viegas, et al.
Published: (2019-03-01)

Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells.
by: Thérèse Keravis, et al.
Published: (2015-01-01)

Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases.
by: Yan Yang, et al.
Published: (2012-01-01)

Improved preparation of C-aryl glucoside SGLT2 inhibitors
by: Yong-Hai Liu, et al.
Published: (2008-08-01)

Effect of Soybean Protein Isolate-7s on Delphinidin-3-<i>O</i>-Glucoside from Purple Corn Stability and Their Interactional Characterization
by: Dongxia Chen, et al.
Published: (2022-03-01)

Fournier's gangrene and sodium-glucose co-transporter 2(SGLT2) inhibitors: Our experience
by: Ashwitha S Dass, et al.
Published: (2019-01-01)

Delphinidin prevents high glucose-induced cell proliferation and collagen synthesis by inhibition of NOX-1 and mitochondrial superoxide in mesangial cells
by: Seung Eun Song, et al.
Published: (2016-04-01)

Pharmacological assessment of delphinidin in counteracting polystyrene microplastic induced renal dysfunction in rats
by: Nimra Nazir, et al.
Published: (2024-11-01)

Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction
by: Adrian I. Abdo, et al.
Published: (2017-10-01)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
by: Annamaria Mascolo, et al.
Published: (2022-09-01)

The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys
by: Eirini Lioudaki, et al.
Published: (2022-03-01)

Safe and pragmatic use of sodium-glucose co-transporter 2 (SGLT 2) inhibitors: medication counseling
by: S. Kalra, et al.
Published: (2016-08-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

Regulation of the intestinal sodium/ glucose cotransporter SGLT1 in health and disease
by: Stearns, A
Published: (2009)

Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis
by: Kai Qu, et al.
Published: (2022-12-01)

High density lipoproteins as indicators of endothelial dysfunction in children with diadetes type I
by: Lobanova S.M., et al.
Published: (2011-12-01)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
by: McGovern, A, et al.
Published: (2017)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

Sodium-glucose transporter-2 (SGLT2; SLC5A2) enhances cellular uptake of aminoglycosides.
by: Meiyan Jiang, et al.
Published: (2014-01-01)

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature
by: Asfandyar Khattak, et al.
Published: (2024-04-01)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014-12-01)

Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications
by: Minoru Kobayashi, et al.

Anti-Adipogenic Effects of Delphinidin-3-<i>O</i>-<i>β</i>-Glucoside in 3T3-L1 Preadipocytes and Primary White Adipocytes
by: Miey Park, et al.
Published: (2019-05-01)

Mitochondrial Dysfunction in Endothelial Progenitor Cells: Unraveling Insights from Vascular Endothelial Cells
by: Azra Kulovic-Sissawo, et al.
Published: (2024-01-01)

High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes
by: Xing Chen, et al.
Published: (2017-09-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
by: Munteanu Madalina Andreea, et al.
Published: (2023-04-01)

Hyaluronidase inhibitor delphinidin inhibits cancer metastasis
by: Jeremy McGuire, et al.
Published: (2024-06-01)

Cytotoxic effects of delphinidin in human osteosarcoma cells
by: Dong-Yeong Lee, et al.
Published: (2018-01-01)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
by: McGovern, A, et al.
Published: (2017)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
by: Kris Aubrey-Bassler, et al.
Published: (2019-02-01)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
by: Yung‐Chih Chen, et al.
Published: (2022-01-01)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014-06-01)

Stress and Vascular Responses: Endothelial Dysfunction via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1: Close Relationships With Oxidative Stress
by: Kanako Sakurai, et al.
Published: (2003-01-01)

Single Center Experience With Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Kidney Transplant Recipients With Diabetes
by: Albi Angjeli, et al.
Published: (2024-11-01)

Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
by: Rabab Mahmoud Ahmed, et al.
Published: (2024-08-01)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
by: Anoushka Krishnan, et al.
Published: (2023-04-01)